• In early June 2026, DaVita Inc. entered into a Ninth Amendment to its 2019 Credit Agreement, adding US$500 million of incremental Tranche B-2 term loans maturing in 2031 to refinance part of its revolving credit facility and fund general corporate purposes.
• This debt move, alongside management’s raised full-year guidance and ongoing share repurchases, highlights DaVita’s current focus on capital structure optimization while signaling confidence in its operating trajectory.
• Against this backdrop of higher guidance and new term borrowing, we will examine how DaVita’s expanded debt profile influences its investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

DaVita Investment Narrative Recap

To own DaVita, you need to believe dialysis will remain a resilient, cash‑generating service and that management can balance debt, buybacks and investment without straining the balance sheet. The new US$500 million Tranche B‑2 term loan modestly increases leverage but mainly refinances existing credit, so it does not materially change the near term focus on stabilizing treatment volumes or the key risk from reimbursement pressure and cost inflation.

The most directly relevant recent announcement is DaVita’s raised full year guidance following Q1 2026 results, supported by improved U.S. treatment volumes and ongoing share repurchases. Together with the fresh term borrowing, this frames a near term catalyst around execution: can DaVita convert its capital structure moves and higher guidance into consistent earnings delivery while managing its elevated debt load and dependence on government programs.

Yet behind this improving guidance, investors should still be aware of...

DaVita's narrative projects $15.7 billion revenue and $1.1 billion earnings by 2029. This requires 4.2% yearly revenue growth and an earnings increase of about $340 million from $756.4 million today.

Uncover how DaVita's forecasts yield a $193.71 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenues of about US$15.3 billion and earnings of roughly US$1.1 billion by 2028, so this new debt raise could either reinforce that upbeat view around margin expansion or, if it amplifies concerns about payer mix and policy risk, push their expectations closer to the more cautious narrative you have seen here.

Explore 2 other fair value estimates on DaVita - why the stock might be worth 32% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.